Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 1/20 | 0.52 |
| ▸ | ATP4B | P51164 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL6481932 | 0.99 | ATP4A (0.51) | ATP4AATP4BPKMDDAH1MAPT | |
| SCHEMBL6374098 | 0.84 | SMN1; SMN2 (0.38) | ATP4AATP4BPKMDDAH1MAPT | |
| SCHEMBL6475286 | 0.84 | LMNA (0.50) | ATP4AATP4BPKMMAPTLMNA | |
| SCHEMBL9693721 | 0.83 | PDE5A (0.42) | ATP4AATP4BLMNAKMT2AALDH1A1 | |
| SCHEMBL9509195 | 0.82 | ALDH1A1 (0.50) | ATP4AATP4BPKMDDAH1MAPT | |
| SCHEMBL8063340 | 0.82 | RAB9A (0.40) | ATP4AATP4BMAPTLMNAMEN1 | |
| SCHEMBL6475609 | 0.81 | ATP4A (0.50) | ATP4AATP4BPKMDDAH1MAPT | |
| SCHEMBL10866312 | 0.80 | PKM (0.44) | PKMDDAH1MAPTLMNAMEN1 | |
| Water SCHEMBL8401632 | 0.80 | ATP4A (0.49) | ATP4AATP4BPKMDDAH1MAPT | |
| Water SCHEMBL8401629 | 0.80 | ATP4A (0.49) | ATP4AATP4BPKMDDAH1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | claimed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | claimed |
| US-5869513-A | ANTIULCER AGENTS | G. D. SEARLE & CO. (US) | 1999-02-09 | — | — | US | claimed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | claimed |
| EP-0213474-A2 | Substituted toluidines, process for their preparation, pharmaceutical compositions containing them and their use as gastric secretion inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-03-11 | — | — | EP | claimed |
| EP-0204215-A1 | 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines | G.D. Searle & Co. (US) | 1986-12-10 | — | — | EP | claimed |
| JP-3223260-A | — | — | None | — | — | JP | disclosed |
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | disclosed |
| EP-0649305-A1 | BENZIMIDAZOLES FOR ALLEVIATING STOMACH ULCERS IN SWINE | MONSANTO COMPANY (US) | 1995-04-26 | — | — | EP | disclosed |
| US-5389664-A | Administering benzimidazole compounds to inhibit at pase activity | MONSANTO COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
| EP-0248634-B1 | STABILIZED BENZIMIDAZOLE DERIVATIVE AND COMPOSITION | NIPPON CHEMIPHAR CO., LTD. (JP) | 1993-07-21 | — | — | EP | disclosed |
| EP-0218336-B1 | USE OF BENZYLSULFINYLBENZIMIDAZOLES AS CYTOPROTECTIVE AGENTS FOR THE GASTROINTESTINAL TRACT | NIPPON CHEMIPHAR CO., LTD. (JP) | 1991-12-18 | — | — | EP | disclosed |
| JP-H03223260-A | BENZIMIDAZOLE DERIVATIVE AND ITS PREPARATION AND ANTI-ULCER AGENT CONTAINING THE SAME | NIPPON CHEMIPHAR CO LTD | 1991-10-02 | — | — | JP | disclosed |
| US-4824856-A | Method of protecting gastrointestinal tract | NIPPON CHEMIPHAR CO., LTD. (JP) | 1989-04-25 | — | — | US | disclosed |
| EP-0248634-A2 | Stabilized benzimidazole derivative and composition | NIPPON CHEMIPHAR CO., LTD. (JP) | 1987-12-09 | — | — | EP | disclosed |
| EP-0218336-A2 | Use of benzylsulfinylbenzimidazoles as cytoprotective agents for the gastrointestinal tract | NIPPON CHEMIPHAR CO., LTD. (JP) | 1987-04-15 | — | — | EP | disclosed |
| EP-0213474-A2 | Substituted toluidines, process for their preparation, pharmaceutical compositions containing them and their use as gastric secretion inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | ATP4A 1/4885ATP4B 8/4885PKM 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.